What combination is referred to as duoneb in treating COPD?

Duoneb is a specific combination therapy used to treat patients with Chronic Obstructive Pulmonary Disease (COPD). It consists of a short-acting beta agonist and a short-acting muscarinic antagonist, which work synergistically to improve airflow and reduce respiratory symptoms.

The short-acting beta agonist component helps to relax and open the airways, making it easier for patients to breathe. Meanwhile, the short-acting muscarinic antagonist helps to block the action of acetylcholine on the muscarinic receptors in the airways, which leads to bronchodilation and further improvement in breathing. This combination is effective in providing quick relief of COPD symptoms, particularly during exacerbations.

Other options involve combinations that do not reflect the specific formulation of Duoneb. The emphasis on using both a short-acting beta agonist and a short-acting muscarinic antagonist is what defines Duoneb's effectiveness in managing acute episodes in COPD patients.